All In Biotech

Drug Trial Radar · NCT06745518

A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

A Phase 2, Randomized, Placebo-controlled, Double-blind, Phosphate Binder-combination Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

Jan 6, 2025

Primary completion

Jul 15, 2025

Study completion Jul 22, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis

Conditions

  • Hyperphosphatemia Patients on Hemodialysis

Interventions

  • TS-172Drug

    oral administration of TS-172 20\~60 mg/day

  • PlaceboDrug

    oral administration of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achievement rate of the target serum phosphorus levelTime frame: Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taisho Pharmaceutical Co., Ltd selected site

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.